Professor Antonio Anzueto
Antonio Anzueto is Professor of Medicine at the University of Texas Health Science Center and Chief of the Pulmonary Section for the South Texas Veterans Health Care System, San Antonio, Texas, USA. In addition, he is a faculty member of the Pulmonary Disease and Critical Care Medicine Division, the Medical Director for the Pulmonary Function Laboratory at the University Hospital in San Antonio, and an adjunct scientist at the Southwest Foundation for Biomedical Research, San Antonio, Texas.
His areas of interest include chronic obstructive pulmonary disease, chronic bronchitis, community-acquired pneumonia, sepsis, acute respiratory distress syndrome, and lung transplantation.
He is a member of a number of medical committees, a reviewer for various scientific journals including the New England Journal of Medicine, and has published over 250 manuscripts in highly rated medical journals. He has extensive research experience as has been the principal investigator of numerous large multicenter clinical trials. He is member of several international committees such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD); ATS/IDSA Community Acquired Pneumonia Guidelines Committee; International committee – consensus conference on ALI/ARDS. He is also a practicing physician that has been nominated over the last 8 years as a “Best Pulmonary Doctor” in San Antonio, Texas.
Prof. Fulvio Braido
Fulvio Braido graduated cum laude in 1993 at the School of Medicine, University of Genoa and participated to the Respiratory Program Respiratory Diseases in 1993-1997 and in Allergy and Clinical Immunology 2002-2006 at the University of Genoa.
He is a researcher in Rhinitis, Asthma, COPD and Sleep Apnea (HI 38).
His main research interests are represented by development and assessmento f patient reported outcomes in respiratory and allergic diseases andthe physiopathological/immunological mechanisms.
Fulvio Braido has an excellent experience in clinical trials based on Good Clinical Practice. He is heavily engaged in teaching activities for the School of Medicine in Genoa, where he teaches Respiratory Diseases.
He is the president of Interasma - Global Asthma Association, former Executive Committee Member of the European Academy of Allergy and Clinical Immunology (EAACI).
He is the editor in chief of Journal of asthma.
Prof. G. Walter Canonica
Allergist and Pulmonologist
Giorgio Walter is Professor of Respiratory Medicine at Humanitas University & Director Personalized Medicine Asthma & Allergy Center at Humanitas Research Hospital-Milano Italy Professor Canonica first specialised in pulmonary diseases after receiving his medical degree from the University of Genoa, Italy. He then specialised in allergy and clinical immunology at Florence University, Italy. He subsequently conducted clinical immunology and allergology research at several European Universities and Institutes, in addition to two years at the Medical University of South Carolina, USA. Since returning to the University of Genoa in 1995, Professor Canonica has held a number of academic positions, including Director of the Speciality School of Allergy and Clinical Immunology, Director of the Specialty School of Pulmonary Diseases and Chairman of the Department of Medical Specialties (University Hospital San Martino Genoa, Italy). He is a Board Member of ARIA-Allergic Rhinitis and its Impact on Asthma and helped to develop their guidelines.
He has been President of WAO-World Allergy Organization, Interasma-Global Asthma Association, currently VicePresident of REG-Respiratory Effectiveness Group.
He is Steering Committee Member of SANI-Severe Asthma Network Italy.
Filipe Froes
PhD in Public Health (Health Policies, Management and Administration)
Head of Intensive Care Unit of Hospital Pulido Valente - Centro Hospitalar Universitário Lisboa Norte
Advisor to the Portuguese Directorate-General for Health / Department of Health
Member of the Portuguese National Council for Public Health
Alan Kaplan
MD CCFP(EM) FCFP
Family Physician practicing in York Region, Ontario, Canada.
Chairperson of the Family Physician Airways Group of Canada (www.fpagc.com)
Past- Chairperson of the Respiratory Section of the College of Family Physicians of Canada
Senate member of the International Primary Care Respiratory Group
President of the IPCRG 5th biennual world scientific meeting, “Making Every Breath Count” Toronto June 2-5, 2010
Chair of the Council of Organizing Members of the Canadian Network for Respiratory Care.
Member of Past Canadian Consensus Guidelines for H pylori, Asthma, COPD and Sinusitis
Representative of the College of Family Physicians of Canada to the SARS clinical working group.
Member of Chronic Respiratory Disease Surveillance Advisory Committee (Public Health Agency of Canada)
Member of the Health Canada Section on Allergy and Respiratory Therapies
Member of the Canadian Metropolitan Tuberculosis Subcommittee
Co-Chair, Health Quality Ontario COPD Community Management standards committee
Board member, Thrombosis Canada
Vice President, Respiratory Effectiveness Group
International editor for Nature’s Primary Care Respiratory Journal
International editor for the Italian Journal of Primary Care
Non-respiratory medical interests:
Community Pain consultant
Palliative Care community physician
Hospitalist, Brampton Civic Hospital
Social:
Married with four children and four dogs
Ardent baseball player
Professor Chin Kook Rhee
Prof. Rhee is an Associate Editor of BMC Pulmonary Medicine. He is a member of editorial board of American Journal of Respiratory and Critical Care Medicine, Journal of COPD, Frontiers in Medicine, Journal of Thoracic Disease, Journal of Korean Medical Science, and Life. He is also a Deputy Editor of Tuberculosis and Respiratory Diseases.
Prof. Rhee is a member of long-range planning committee of ERS Assembly 5, Chairperson of APSR Research Committee, Head of APSR COPD assembly, a member of Planning and Action Committee on APSR Development, APSR Bulletin Coordinator. He is a member of steering committee of International Severe Asthma Registry. He is also a member of many committees of Korean Academy of Tuberculosis and Respiratory Disease.
Prof. Rhee has published 230 SCI(E) articles (95 publications as first/corresponding author). The focus of his research is COPD and asthma.
Thérèse Lapperre
Dr. Désirée Larenas-Linnemann
- Directora Centro de Excelencia en Asma y Alergia, Hospital Médica Sur, Mexico City
- GINA Advocate for Mexico 2020-ongoing
- Chair 8 National Guidelines: a.o. Integrated asthma managemente (MIA 2021), Immunotherapy 2019, Consensus Atopic Derm 2018, Asthma 2017, Urticaria 2014 and ARIA México 2014
>190 pubmed indexed publications
Dr Marc Miravitlles
Marc Miravitlles is a Pulmonologist at the Hospital Universitari Vall d’Hebron in Barcelona, Spain. He obtained his MD at the Universitat de Barcelona, Barcelona, Spain and then specialised in Respiratory Medicine at Hospital Vall d'Hebron. His primary research interests include chronic obstructive pulmonary disease (COPD), alpha-1-antitrypsin deficiency (AAT), lung defence mechanisms and respiratory infections. He serves on various medical committees and is a member of numerous professional societies, including the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), where he served as Secretary from 1999 until 2003 and responsible for International Relationships from 2006 until 2012. Dr Miravitlles was Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) from 2008 to 2011 and was the Guidelines Director of the ERS from 2015 to 2018. He has acted as a consultant for the development of different international guidelines of COPD, including the American Thoracic Society (ATS)/ERS task force on outcomes in COPD, the ERS/ATS guidelines on exacerbations of COPD and the ERS statement on management of alpha-1 antitrypsin deficiency. He is also a consultant of the Spanish Ministry of Health for the development of the National Strategy Against COPD (2009 to present). He is the coordinator of the Spanish National Guidelines for COPD (GesEPOC from 2012).
Professor Nikolaos (Nikos) Papadopoulos
He has extensive clinical and educational experience in paediatric allergy, having headed for many years a unit caring for more than 7,000 children with allergic diseases yearly, implementing state-of-the-art interventions and training medical students, resident paediatricians and allergists.
His research focus is the interface between infection and allergic disease, with an emphasis on asthma exacerbations and food allergy. He is the Coordinator of the EU-funded CURE project. He has extensive collaborations in the context of EU projects, such as PreDicta, GA2LEN, EUROPREVALL, iFAAM and FAST.
Prof. Papadopoulos has published over 300 papers (h-index: 70), has received several international awards and is invited to speak at international scientific meetings some 30 times a year. Moreover, he has served or is serving on the boards of EAACI, GA2LEN, WAO, EFA and ARIA. He was the 2013–2015 President of EAACI and is currently the President of the Respiratory Effectiveness Group (REG).
Prof. Alberto Papi
He trained in Respiratory Medicine at the University of Parma, before spending 4 years in the UK as a Clinical Research Fellow at the University of Southampton, where he is an Honorary Clinical Lecturer.
He has coordinated several pivotal studies in asthma and COPD, and has authored more than 350 articles in peer-reviewed journals.
Prof. David Price
Nicolas Roche
Nicolas Roche is Professor of Respiratory Medicine at Cochin Hospital, University of Paris Descartes, France. His major areas of interest are COPD and asthma with particular focus on inhaled therapy, disease phenotypes, assessment tools, treatment strategies and real-life research.
Professor Roche is a member of the GOLD science committee, President of Société de Pneumologie de Langue Française, co-chair of the 2018 ERS Congress and member of the American Thoracic Society. He is guidelines director of the ERS and member of the ERS Clinical Research Collaboration (CRC) working group and ERS Science Council, vice-president of the Respiratory Effectiveness Group and member of the Asthma Drug Management Improvement Team. He coordinates French guidelines on COPD and is a consultant for French institutions for the development of national projects on COPD.
Professor Roche has authored more than 250 research articles in international peer-reviewed journals and edited or co-edited several books on COPD. He is Associate Editor of the European Respiratory Review and the Clinical Respiratory Journal.
Dr Joan B. Soriano, M.D., Ph.D., FERS, FCCP
Associate Professor of Medicine, Universidad Autónoma de Madrid, and Senior Investigator at the Instituto de Investigación Hospital Universitario de la Princesa-IISP, Madrid, Spain
Bariton at the Opera Choir of Teatre Principal de Palma, Palma de Mallorca, Spain
Joan B Soriano graduated in Medicine in 1993 and received his Ph.D. in Epidemiology and Methodology of Biomedical Research in 1996, both from the Universitat Autònoma de Barcelona. He completed his education in Epidemiology with a Master of Science at the Erasmus University Rotterdam, The Netherlands, and a post-doctoral stay at the Johns Hopkins School of Public Health, in Baltimore, USA. He worked in the pharmaceutical industry in the UK from 1998, and later in the USA from 2003. In 2005 moved back to CIMERA in Mallorca, Spain, up to its closing. From 2015, he is Associate Professor of Medicine at the Universidad Autónoma de Madrid, Senior Investigator at the Instituto de Investigación Hospital Universitario de la Princesa-IISP, both in Madrid.
He serves in the GesEPOC COPD guidelines, has been Methodologic and Scientific Consultant of SEPAR and Director of its Foreign Affairs, participates in several committees of the Ministry of Health of Spain, and collaborates extensively with both the ERS and CHEST. He spends most of his time dedicated to research on COPD and other respiratory conditions, aging and tobacco, the design of new clinical trials and translational Medicine. Since 2007 he is Associate Editor of the European Respiratory Journal and since 2012 of the Lancet Respiratory Medicine, and peer reviews extensively for others. He has 300+ publications in PubMed in the fields of clinical epidemiology and treatment of respiratory diseases, and a Hirsh index of 80+. In May 2011 he received the Josep Trueta Award for scientific and medical achievements, and in 2014 he was appointed FCCP from Chest and Foundational Fellow of the ERS (FERS).
He has authored several REG papers and participated actively in many of its past conferences. He is in the REG Board since 2019.
Omar Usmani
Omar Usmani is a Reader and Consultant Physician in Respiratory Medicine at the National Heart and Lung Institute (NHLI), Imperial College London and Royal Brompton Hospital. He qualified in Medicine at King’s College London and completed his PhD at Imperial College London for which he received the 2005 NHLI Imperial College PhD Prize for the best thesis.
His clinical research themes are Inhaled Drug Delivery, Airways Physiology, Lung Imaging, Respiratory Pharmacology and Tele-monitoring / E-health. He is Secretary of Assembly 5 (Asthma and COPD) at the ERS, Chair of UKIG (UK Inhaler Group), Vice-Chair of Drug Delivery to the Lungs, and Europe Liaison of International Society of Aerosols in Research (ISAM).
In 2012, he was awarded a UK National Institute for Health Research (NIHR) Career Development Fellowship, the first time this award category was given to Respiratory Science research in the UK. In 2015, received one of the highest accolades in aerosol science, the Thomas T Mercer Award from the American Association of Aerosol Research (AAAR) and ISAM, recognizing his international research excellence in pharmaceutical aerosols and inhalable materials.
He is currently clinical lead on an EU Horizon 2020 consortium project ‘myaircoach’ focusing on the tele-monitoring of patients with asthma and is PI of an FDA awarded project on understanding patient perceptions in breathing from a DPI.
Prof. Job van Boven
He obtained his PharmD and PhD at the University of Groningen (The Netherlands), where his thesis focused on the cost-effectiveness of adherence enhancing interventions in patients with COPD. After his PhD research, he completed fellowships at the University of Colorado (USA), Monash University (Australia) and the Hospital Universitario Son Espases (Spain).
He is (co)author of >100 scientific publications, supervisor of 9 PhD students and received several research prices & grants (totalling>€6 million). Having interest and wide experience in both medication adherence and health economic methods, his mission is to find novel, cost-effective ways to make better use of our respiratory medications in order to maximize both patients’ and societal benefits. Amongst others, his research aims to provide evidence for optimal implementation of drug-device technologies (digital inhalers, electronic pill bottles and smart spacers) in daily clinical practice.
Mario Cazzola
His research has mainly been focused on the pharmacology of airway diseases, particularly the use of bronchodilators and obstructive lung diseases. He is the author or co-author of almost 831 scientific papers. His H-index is 78 (Scholar). According to Expertscape (October 2024), he is the top-rated expert in COPD, obstructive lung diseases, and bronchodilator agents in the world during the years 2014-2024. He has been ranked 1489 of Top Scientists in the field of Medicine in the world according with the 2024 Edition of Research.com.
He founded Therapeutic Advances in Respiratory Diseases and served as its first Editor-in-chief and served as the Editor-in-Chief for Pulmonary Pharmacology & Therapeutics, and for COPD – Research and Practice. He serves as the Deputy Editor for Respiratory Medicine, Section Editor for Frontiers in Drug Safety and Regulation, and an Associate Editor for Respiratory Research, Current Research in Pharmacology and Drug Discovery, Clinical Investigation, and The Open Respiratory Medicine Journal, and an Editor for British Journal of Pharmacology. He is or was an Editorial Board Member for Lancet Respiratory Medicine, Respiration, International Journal of Chronic Obstructive Pulmonary Disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Monaldi Archives for Chest Diseases, International Journal of Respiratory Care, Current Pulmonary Medicine Reviews, Current Drug Therapy, Current Patents on Anti-Infective Drug Discovery, Expert Review of Respiratory Medicine, Journal of Pharmacogenomics & Pharmacoproteomics, Therapeutic Advances in Chronic Diseases.
He was the Chairman of the Airway Pharmacology and Treatment Group, the Secretary of the Inflammatory Airway Diseases and Clinical Allergy Assembly, the Postgraduate Courses Director, and an Internal Auditor at the European Respiratory Society (ERS).
He was the Co-chairman of the ERS/ATS Task Force "Outcomes for COPD pharmacological trials: from lung function to biomarkers".
He is a Fellow of the ERS since 2014 and has received the 2015 Lifetime Achievement Award from the same scientific society.
He was a member of the steering committee of the Airway Disorders Network and was serving as Governor of the Italian Chapter at the American College Chest Physicians.
He is the Chairman of the Southern Europe Chapter at Interasma, and the Chair of the Med COPD Forum.
He was a referee of the Continual Medical Education Programs of the Italian Health Ministry.
He was a referee for IMI projects/European Community in 2009 and 2012.
He was a referee for the Agence Nationale de la Recherche (France) in 2016 and 2017.
He has been a member of the editorial board chaired by the Italian Minister of Heath for the report on the health status in Italy in 2011.
He has acted as referee/assessor for different Universities and Agencies worldwide.
Amy Chan
Prof. dr. Frits M.E. Franssen
Professor Ralph Mösges, M.D. Ph.D. FAAAAI
Ralph Mösges is the author and editor of ten books and has published more than 400 articles in major journals. He is an editor of the immunology section of The Journal of Clinical Medicine .
Jennifer Quint
Prof Quint leads the Respiratory Electronic Health Record group, a clinical epidemiology research group whose interests centre on using various sources of de-identified, routinely collected electronic healthcare records to study a number of respiratory diseases including chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, bronchiectasis and most recently COVID-19. Work centres on maximising the quality, linkage and usage of these data for clinical and research purposes. Research topics include understanding the relationship between cardiovascular and respiratory disease, respiratory disease prevention, diagnosis, natural history and management. Many of the outputs are used for informing policy, and in the planning and allocation of resources.
She is a Fellow of the Higher Education Academy and the Royal College of Physicians. She works closely with NHSE England on data and metrics across a number of respiratory parameters, partners with the Royal College of Physicians where she is the Analysis Lead for the National Respiratory Audit Programme and is co-lead of the HDR UK Inflammation and Immunity Driver Program. She currently serves as joint Editor-in-chief of the journal Thorax.
Dr. Dermot Ryan
Adnan Custovic
In 2020, he was elected to the Fellowship of the UK Academy of Medical Sciences. In 2023 he was elected as EAACI Fellow (FEAACI). He was elected as NIHR Senior Investigator in 2023. In 2021, he was awarded a Fellowship of the Association of Physicians of Great Britain and Ireland (FaOP). In 2015 he was awarded ERS Gold Medal for research in asthma. In 2013 he received the BSACI William Frankland Medal for outstanding contributions to clinical allergy in the UK. He delivered numerous prestigious keynote/named lectures. He publisher >450 papers in peer-reviewed journals, with>60,000 citations and h-index of 114.
He serves at the Board of Directors of the World Allergy Organisation and has served as a Secretary of the BSACI for two terms, and as President of Asthma section of the EAACI.
He has supervised 19 PhD/MD students to completion.
Maureen Donahue Hardwick
Maureen Donahue Hardwick serves as the Secretariat and Legal Counsel of the International Pharmaceutical Aerosol Consortium (IPAC) and has been in the role since 2000. IPAC’s mission is to ensure that environmental policies relevant to inhaled therapies are patient-centric and appropriately balance both patient care and sustainability objectives. IPAC has developed principles to help guide policy discussions that reflect the lessons learned in our work on the Montreal Protocol on Substances that Deplete the Ozone Layer. IPAC is comprised of AstraZeneca, Bespak, Boehringer Ingelheim, Chiesi Farmaceutici, Cipla, GSK, Kindeva, and Teva. IPAC members produce MDIs in the UK, Europe, United States and other countries and supply MDIs to patients worldwide.
She is based in Washington, DC and is also a partner at the law firm, Faegre, Drinker, Biddle & Reath, LLC.